Concepedia

Author

Akihiro Ohba

National Cancer Center Hospital EastORCID

Also Known As

A. Ohba, Akihiro OHBA, Akihiro Ohba

103

Publications

1.1K

Citations

15

H-Index

41

Concepts

All Affiliations

National Cancer Center Hospital EastTokyo National HospitalKyorin UniversityKanagawa Prefectural Hospital OrganizationKanagawa Cancer Center
AO

About

Akihiro Ohba is an author at National Cancer Center Hospital East specializing in medicine, oncology, and cancer research.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

9

9

290

2

Engineering

2

2

49

3

Health Sciences

1

1

103

4

Natural Sciences

1

1

28

5

Biochemistry

1

1

28

Akihiro Ohba

×

24

Publications

853

Citations

14

H-Index

YearCitations

Clinical Practice Guidelines for Pancreatic Cancer 2022 from the Japan Pancreas Society: a synopsis

Takuji Okusaka, Masahiro Yoshida, Masayuki Kitano,

International Journal of Clinical Oncology

2023

153

Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing unresectable or recurrent biliary tract cancer (BTC): An investigator-initiated multicenter phase 2 study (HERB trial).

Akihiro Ohba, Chigusa Morizane, Yasuyuki Kawamoto,

Journal of Clinical Oncology

2022

103

A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407)

Masato Ozaka, Kohei Nakachi, Satoshi Kobayashi,

European Journal of Cancer

2022

74

Multicenter phase II trial of trastuzumab deruxtecan for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial

Akihiro Ohba, Chigusa Morizane, Makoto Ueno,

Future Oncology

2022

63

Difference in SARS-CoV-2 Antibody Status Between Patients With Cancer and Health Care Workers During the COVID-19 Pandemic in Japan

Shu Yazaki, Tatsuya Yoshida, Yuki Kojima,

JAMA Oncology

2021

56

1616O Nab-paclitaxel plus gemcitabine versus modified FOLFIRINOX or S-IROX in metastatic or recurrent pancreatic cancer (JCOG1611, GENERATE): A multicentred, randomized, open-label, three-arm, phase II/III trial

Akihiro Ohba, Masato Ozaka, Gakuto Ogawa,

Annals of Oncology

2023

51

Trastuzumab Deruxtecan in Human Epidermal Growth Factor Receptor 2–Expressing Biliary Tract Cancer (HERB; NCCH1805): A Multicenter, Single-Arm, Phase II Trial

Akihiro Ohba, Chigusa Morizane, Yasuyuki Kawamoto,

Journal of Clinical Oncology

2024

40

Details of human epidermal growth factor receptor 2 status in 454 cases of biliary tract cancer

Nobuyoshi Hiraoka, Hiroaki Nitta, Akihiro Ohba,

Human Pathology

2020

38

Fine‐needle biopsy with 19G needle is effective in combination with endoscopic ultrasound‐guided tissue acquisition for genomic profiling of unresectable pancreatic cancer

Go Ikeda, Susumu Hijioka, Yoshikuni Nagashio,

Digestive Endoscopy

2022

37

Proportion of unresectable pancreatic cancer specimens obtained by endoscopic ultrasound-guided tissue acquisition meeting the OncoGuide™ NCC Oncopanel System analysis suitability criteria: a single-arm, phase II clinical trial

Yuya Hisada, Susumu Hijioka, Go Ikeda,

Journal of Gastroenterology

2022

29

Page 1